|Year : 2020 | Volume
| Issue : 4 | Page : 941-945
Long-term survival of a patient with programmed death ligand 1-negative lung adenocarcinoma and oligoprogressive disease treated with nivolumab and stereotactic body radiation therapy
Miguel J Sotelo1, Santiago Cabezas-Camarero2, Alejandro Riquelme1, Coralia Bueno1
1 Department of Medical Oncology, Hospital Universitario Infanta Cristina, Madrid, Spain
2 Department of Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid, Spain
|Date of Submission||31-Jan-2019|
|Date of Decision||17-Apr-2019|
|Date of Acceptance||11-Sep-2019|
|Date of Web Publication||09-Jun-2020|
Miguel J Sotelo
Department of Medical Oncology, Hospital Universitario Infanta Cristina, Avenida 9 de Junio, 228981 Parla, Madrid
Source of Support: None, Conflict of Interest: None
Immune-checkpoint inhibitors have shown to prolong survival in patients with metastatic non-small cell lung cancer. Programmed death ligand 1 (PD-L1) expression is associated with a higher probability of response, although some patients with PD-L1 negative tumors may also respond or show durable stabilizations. However, the optimal strategy after progression to immunotherapy (IO) is not yet defined. Patients with oligometastatic disease may benefit from local treatments such as radiotherapy (RT), achieving significant local control rates. In addition, RT is claimed to have numerous immunogenic effects that could synergize with IO. We present the case of a complete responder to nivolumab that after a monotopic adrenal relapse received stereotactic body radiation therapy, followed by maintenance nivolumab achieving a partial response that is still ongoing. Aspects such as mechanisms of acquired resistance to PD-L1 inhibitors, the optimal management after progression, and the potential interplay between IO and RT are briefly reviewed and discussed.
Keywords: Lung adenocarcinoma, nivolumab, oligoprogressive disease, stereotactic body radiation therapy, synergistic effects
|How to cite this article:|
Sotelo MJ, Cabezas-Camarero S, Riquelme A, Bueno C. Long-term survival of a patient with programmed death ligand 1-negative lung adenocarcinoma and oligoprogressive disease treated with nivolumab and stereotactic body radiation therapy. J Can Res Ther 2020;16:941-5
|How to cite this URL:|
Sotelo MJ, Cabezas-Camarero S, Riquelme A, Bueno C. Long-term survival of a patient with programmed death ligand 1-negative lung adenocarcinoma and oligoprogressive disease treated with nivolumab and stereotactic body radiation therapy. J Can Res Ther [serial online] 2020 [cited 2020 Sep 26];16:941-5. Available from: http://www.cancerjournal.net/text.asp?2020/16/4/941/286254
| > Introduction|| |
Programmed death ligand 1 (PD[L] 1) inhibitors increase tumor responses and prolong survival in patients with non-small cell lung cancer (NSCLC) progressing to platinum-based chemotherapy, a scenario historically associated with a dismal prognosis. However, only a small subgroup, of up to 20% of cases, may actually respond to these agents.,,
PD-L1 expression can help in the selection of patients that will benefit from PD(L)1 inhibitors, but it is not an accurate biomarker. Indeed, some PD-L1-negative patients may show brilliant and durable responses to these agents.
Patients with oncogene-driven lung cancer oligoprogressing, while on tyrosine kinase inhibitors (TKIs), are commonly managed with local interventions (i.e., surgery, radiotherapy [RT]) followed by maintenance TKI therapy. However, there is insufficient evidence yet to adopt a similar strategy in patients oligoprogressing to immunotherapy (IO) agents.
Stereotactic body radiation therapy (SBRT) allows the administration of very high RT doses while minimizing the irradiation of the adjacent normal tissues. In addition to its direct antitumor activity, RT has powerful immunogenic effects that support its combination with immune-checkpoint inhibitors.
We present the case of a patient with lung adenocarcinoma initially responding to nivolumab, and a monotopic right adrenal progression that was treated with SBRT followed by maintenance nivolumab without evidence of disease progression to date.
| > Case Report|| |
A 64-year-old woman, active smoker of 30 pack-years, consulted in October 2014, because of a soft-tissue lesion of 4.8 cm × 3.5 cm in the abdominal wall. After a complete excisional biopsy, pathology informed of a metastasis of lung adenocarcinoma, epidermal growth factor receptor, and anaplastic lymphoma kinase negative. In December 2014, computed tomography (CT) scan showed a 2.4 cm × 1.2 cm pulmonary nodule in the left upper lobe, a 1-cm subcutaneous chest implant and a 1-cm left adrenal lesion [Figure 1]. A 18F-fluorodeoxyglucose (FDG)-positron emission tomography/CT (PET/CT) scan showed pathological FDG uptake in the pulmonary nodule and left adrenal lesion as well as in multiple subcutaneous implants.
|Figure 1: (a and b) Computed tomography scan in December 2014 showing a 2.4 cm × 1.2 cm pulmonary nodule in the left upper lobe and a 1 cm subcutaneous chest implant. (c and d) Computed tomography scan after 4 cycles of cisplatin plus pemetrexed, showing a complete radiological response|
Click here to view
Four cycles of cisplatin plus pemetrexed were administered between January and April 2015, achieving a complete radiological response [Figure 1] followed by maintenance with pemetrexed (four additional cycles) until June 2015, when CT scan showed recurrence of the left upper lobe nodule, which measured 2.1 cm × 1.2 cm [Figure 2].
|Figure 2: (a) Computed tomography scan in June 2015 before the start of nivolumab showing a 2.1 cm × 1.2 cm left upper lobe nodule. (b) Computed tomography scan after 7 cycles of nivolumab, showing a complete radiological response|
Click here to view
In August 2015, treatment with nivolumab was started. A complete radiological response was achieved after seven cycles [Figure 2], and it was maintained for a total of 26 cycles until August 2016, when a right adrenal lesion of 3.2 cm × 2.7 cm was evidenced. Nivolumab was continued and a 18F-FDG-PET/CT scan was performed in October 2016, that only showed pathological FDG uptake (maximum standardized uptake value 10.5) on the right adrenal lesion, which then measured 4 cm [Figure 3]. Nivolumab was continued, and SBRT was administered in the right adrenal metastasis in December 2016 (45 Gy in 9 fractions of 5 Gy), achieving a 70% reduction in the size of the lesion (1.2 cm in the control CT scan) in February 2017 [Figure 3].
|Figure 3: (a and b) Computed tomography and positron emission tomography scans in October 2016, showing a single adrenal lesion with pathological fluorodeoxyglucose uptake and measuring 4 cm (c) Computed tomography scan in February 2017 showing a partial response after stereotactic body radiation therapy. (d) Computed tomography scan in August 2018 showing a sustained partial response|
Click here to view
Interestingly, PD-L1 expression was performed in March 2017 in the biopsy of initial diagnosis, and it was negative (<1%).
The patient is still on treatment to date and continues showing a sustained partial response [Figure 3] with good tolerance (asthenia Grade 1, anorexia Grade 2) and no evidence of immune-related toxicity.
| > Discussion|| |
PD(L)1 inhibitors have shown to prolong survival in patients with NSCLC who have progressed to platinum-based chemotherapy, achieving long-lasting responses in a subset of patients.,, Unfortunately, therapeutic options are scarce after progression to these agents, and the prognosis is poor.
Patients with oncogene-driven lung cancer with oligoprogressive disease during TKI therapy may benefit from local treatments, maintaining the same TKI. Although this therapeutic strategy is not yet common practice in patients treated with immune-checkpoint inhibitors, it could be an option for those patients who after showing a sustained control of the disease, progress in a limited number of metastatic locations. In addition, evidence from prospective and retrospective studies supports the use of aggressive local therapies in patients with NSCLC and oligometastatic disease, as this strategy may significantly increase survival in selected patients.
RT is a widely used therapeutic tool in oligometastatic lung cancer. In particular, SBRT is increasingly employed, given the high biologic doses that can be administered with minimal toxicity. Our patient obtained a complete radiological response with nivolumab and after a year of treatment, presented right adrenal progression. Given the important benefit obtained so far and the monotopic nature of the progression, SBRT was administered in the right adrenal metastasis, followed by continuation of nivolumab. This strategy has allowed to control the disease to date with minimal toxicity, in a setting with few and minimally effective chemotherapy options. Although adrenalectomy for single adrenal metastases has shown favorable results, the use of SBRT is currently preferred given its favorable safety profile, high rates of local control, and prolonged survival demonstrated in multiple published series [Table 1].
|Table 1: Series of nonsmall cell lung cancer patients and adrenal metastases treated with stereotactic body radiation therapy|
Click here to view
We chose SBRT considering its well-known local effects, low morbidity, and potential synergy with IO. Thus, the known immunogenic effects of RT may have favored the prolonged disease stabilization with nivolumab after SBRT. Although RT exerts a direct antitumor effect, it also induces immunogenic cell death through the promotion of antigen presentation, effector T-cell activation, and regulatory T-cell inhibition., Several preclinical studies and a few case reports suggest a powerful synergy from the combination of RT and IO. Indeed, increases in PD-L1 expression have been described as an adaptive immune resistance mechanism after RT. On the other hand, higher radiation doses per fraction, as those administered with SBRT, seem to synergize better with PD(L)1 inhibition compared to standard fractionation regimens of several weeks duration, that usually are more toxic and less convenient for the patients. Of note, the magnitude and duration of the response seen in our patient, with a 70% reduction in the size of the right adrenal lesion, may not simply be the result of SBRT, but instead, reflect the presumed synergy derived from PD-L1 inhibition and RT [Figure 3]. Finally, it could be hypothesized that both RT and IO could enhance the systemic control of the disease through an abscopal-like effect by favoring antigen presentation. In the PACIFIC trial, the increased progression-free survival and overall survival observed in the durvalumab arm may have been, in part, related to the recent administration of chemoradiation. Currently, multiple clinical trials (some of them in the metastatic setting) are evaluating the combination of IO and RT in patients with lung cancer [Table 2]. These studies will provide information about the optimal dose, timing, activity, and safety of this therapeutic strategy.
|Table 2: Studies evaluating the combination of immune checkpoint blockade and radiotherapy in nonsmall cell lung cancer|
Click here to view
While a high expression of PD-L1 may be associated with a higher probability of response to immune checkpoint blockade, PD-L1 negative tumors may also respond or show durable stabilizations., Indeed, it is well known that PD-L1 expression is dynamic and may be modulated by both local and systemic treatments. In our patient, prior administration of cisplatin-based chemotherapy may have favored tumor antigen presentation and immune cell activation, thus potentially enhancing the response to subsequent nivolumab.
The duration of treatment is also a point to discuss. We decided to continue nivolumab after SBRT, given the prolonged control of the disease and excellent tolerance in an initially widely metastatic patient. The CheckMate 153 study demonstrated that continuing nivolumab after 1 year of treatment was significantly associated with better progression-free survival (hazard ratio 0.43, 95% confidence interval, 0.25–0.76) with a trend toward better overall survival. Likewise, treatment with nivolumab beyond progression may be associated with increased survival and even objective responses in NSCLC and other solid tumors.,,
| > Conclusion|| |
In patients with previous long-lasting response to PD(L)1 inhibitors and oligoprogressive disease, irradiation of the progressing lesions followed by the reintroduction of IO is an option to consider given the limited therapeutic options, good safety profile, and the potential synergistic effects between RT and IO.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| > References|| |
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al.
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N
Engl J Med 2015;373:1627-39.
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016;387:1540-50.
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65.
Maleki Vareki S, Garrigós C, Duran I. Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol 2017;116:116-24.
Basler L, Kroeze SG, Guckenberger M. SBRT for oligoprogressive oncogene addicted NSCLC. Lung Cancer 2017;106:50-7.
Bergsma DP, Salama JK, Singh DP, Chmura SJ, Milano MT. Radiotherapy for oligometastatic lung cancer. Front Oncol 2017;7:210.
Walshaw RC, Honeychurch J, Illidge TM. Stereotactic ablative radiotherapy and immunotherapy combinations: Turning the future into systemic therapy? Br J Radiol 2016;89:20160472.
Porte H, Siat J, Guibert B, Lepimpec-Barthes F, Jancovici R, Bernard A, et al.
Resection of adrenal metastases from non-small cell lung cancer: A multicenter study. Ann Thorac Surg 2001;71:981-5.
Katoh N, Onimaru R, Sakuhara Y, Abo D, Shimizu S, Taguchi H, et al.
Real-time tumor-tracking radiotherapy for adrenal tumors. Radiother Oncol 2008;87:418-24.
Chawla S, Chen Y, Katz AW, Muhs AG, Philip A, Okunieff P, et al.
Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys 2009;75:71-5.
Holy R, Piroth M, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 2011;187:245-51.
Oshiro Y, Takeda Y, Hirano S, Ito H, Aruga T. Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. Am J Clin Oncol 2011;34:249-53.
Torok J, Wegner RE, Burton SA, Heron DE. Stereotactic body radiation therapy for adrenal metastases: A retrospective review of a noninvasive therapeutic strategy. Future Oncol 2011;7:145-51.
Casamassima F, Livi L, Masciullo S, Menichelli C, Masi L, Meattini I, et al.
Stereotactic radiotherapy for adrenal gland metastases: University of Florence experience. Int J Radiat Oncol Biol Phys 2012;82:919-23.
Scorsetti M, Alongi F, Filippi AR, Pentimalli S, Navarria P, Clerici E, et al.
Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients. Acta Oncol 2012;51:618-23.
Guiou M, Mayr NA, Kim EY, Williams T, Lo SS. Stereotactic body radiotherapy for adrenal metastases from lung cancer. J Radiat Oncol 2012;1:155-63.
Ahmed KA, Barney BM, Macdonald OK, Miller RC, Garces YI, Laack NN, et al.
Stereotactic body radiotherapy in the treatment of adrenal metastases. Am J Clin Oncol 2013;36:509-13.
Rudra S, Malik R, Ranck MC, Farrey K, Golden DW, Hasselle MD, et al.
Stereotactic body radiation therapy for curative treatment of adrenal metastases. Technol Cancer Res Treat 2013;12:217-24.
Gamsiz H, Beyzadeoglu M, Sager O, Demiral S, Dincoglan F, Uysal B, et al.
Evaluation of stereotactic body radiation therapy in the management of adrenal metastases from non-small cell lung cancer. Tumori 2015;101:98-103.
Plichta K, Camden N, Furqan M, Hejleh TA, Clamon GH, Zhang J, et al.
SBRT to adrenal metastases provides high local control with minimal toxicity. Adv Radiat Oncol 2017;2:581-7.
Celik E, Semrau R, Baues C, Trommer-Nestler M, Baus W, Marnitz S. Robot-assisted extracranial stereotactic radiotherapy of adrenal metastases in oligometastatic non-small cell lung cancer. Anticancer Res 2017;37:5285-91.
Morisada M, Chamberlin M, Allen C. Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer. Head Neck 2018;40:1321-34.
Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al.
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014;74:5458-68.
Nagasaka M, Zaki M, Kim H, Raza SN, Yoo G, Lin HS, et al.
PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: A case report. J Immunother Cancer 2016;4:83.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al.
Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N
Engl J Med 2017;377:1919-29.
Spigel DR, McLeod M, Hussein MA, Waterhouse DM, Einhorn L, Horn L, et al
. 1297ORandomized results of fixed-duration (1-yr) vs. continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann Oncol 2017;28 Suppl 5:mdx380.002.
Cappuzzo F, Delmonte A, Capici S, Crinò L, Logroscino AF, Sandri P, et al
. P1.06-006 Treatment beyond progression in patients with advanced squamous NSCLC participating in the expanded access programme (EAP). J Thorac Oncol 2017;12 Suppl:S667-8.
Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, et al.
Nivolumab for patients with advanced melanoma treated beyond progression: Analysis of 2 phase 3 clinical trials. JAMA Oncol 2017;3:1511-9.
Haddad R, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al
. 1043OTreatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes. Ann Oncol 2017;28 Suppl 5:mdx374.001.
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2]